系统性硬皮病中炎症性关节炎的治疗。

Treatment of Inflammatory Arthritis in Systemic Sclerosis.

机构信息

Rheumatology Division, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), Rua Botucatu 740, 3 andar, São Paulo, São Paulo 04023-062, Brazil.

出版信息

Rheum Dis Clin North Am. 2023 May;49(2):337-343. doi: 10.1016/j.rdc.2023.01.008. Epub 2023 Mar 1.

DOI:10.1016/j.rdc.2023.01.008

PMID:37028838

Abstract

Joint involvement, including arthralgia, inflammatory arthritis, joint contractures and overlapping with rheumatoid arthritis, is a common manifestation and is associated with impared quality of life in systemic sclerosis (SSc). Few studies have evaluated the treatment of arthritis in SSc. Pharmacological approach includes low-dose corticosteroids, methotrexate, and hydroxychloroquine. Non-tumor necrosis factor biologics, especially rituximab and tocilizumab, may be a promising option for refractory cases.

摘要

关节受累，包括关节痛、炎性关节炎、关节挛缩以及与类风湿关节炎重叠，是系统性硬化症（SSc）的常见表现，并与生活质量受损相关。目前很少有研究评估 SSc 关节炎的治疗。药物治疗包括低剂量皮质类固醇、甲氨蝶呤和羟氯喹。对于难治性病例，非肿瘤坏死因子生物制剂，特别是利妥昔单抗和托珠单抗，可能是一种有前途的选择。